{"entity":{"id":"nct07258121","kind":"trial","name":"Study of ZGGS34 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ZG006 in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","summary":"Study of ZGGS34 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07258121 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 400 participants planned, started 2025-12-31 and due to reach its primary completion in 2028-12. Interventions recorded: ZG006.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07258121","url":"https://clinicaltrials.gov/study/NCT07258121"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["zg006"],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07258121","phase":"1/2","setting":"A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZGGS34 in Participants With Advanced Solid Tumors","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","enrolled":400,"outcomes":[]},"route":"/trials/nct07258121/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}]}}